



## **SUPPLEMENTARY MATERIAL**

### **Primary exposure to Zika virus increases risk of symptomatic dengue virus infection with serotypes 2, 3, and 4 but not serotype 1**


Jose Victor Zambrana<sup>1,2†</sup>, Chloe M. Hasund<sup>3†</sup>, Rosemary A. Aogo<sup>3†</sup>, Sandra Bos<sup>4</sup>, Sonia Arguello<sup>1</sup>, Karla Gonzalez<sup>1,5</sup>, Damaris Collado<sup>1</sup>, Tatiana Miranda<sup>1</sup>, Guillermina Kuan<sup>1,6</sup>, Aubree Gordon<sup>2</sup>, Angel Balmaseda<sup>1,5</sup>, Leah Katzelnick<sup>3\*</sup>, Eva Harris<sup>4\*</sup>



**Fig. S1. Risk of dengue differs by infection history on crude levels.** Crude risk of symptomatic DENV infection by prior DENV and ZIKV infection histories, 2022-2023.



**Fig. S2. Prior infection history confers differential risk of symptomatic DENV1-4 considering baseline spatial risk.** Risks ratios of symptomatic and severe dengue by prior DENV and ZIKV infection histories including age-adjusted flavivirus seroprevalence of the prior year on the neighborhood level as a covariate (A) in the 2022-2023 epidemic season (B-C) in the entire cohort season (2004-2023).



**Fig. S3. Most secondary infections in 2022 had DENV2 and/or ZIKV infections as a primary infection.** Frequency of DENV cases (A) and cases due to DENV1 (B), DENV2 (C), DENV3 (D), and DENV4 (E) infections in 2022 by years since last infection for each infection history. The flavivirus-naïve group contains years since entered the cohort.

**Table S1. Characteristics of participants in the Pediatric Dengue Cohort Study with documented infection histories, 2004-2023**

Variable	DENV Cases						P-value <sup>2</sup>
	Overall, N = 1,418 <sup>1</sup>	DENV1, N = 294 <sup>1</sup>	DENV2, N = 481 <sup>1</sup>	DENV3, N = 310 <sup>1</sup>	DENV4, N = 135 <sup>1</sup>	Dengue Serology, N = 178 <sup>1</sup>	
<b>Age</b>	9.5 (6.8, 12.2)	9.9 (7.4, 12.5)	9.5 (7.0, 12.1)	8.8 (6.0, 11.1)	11.9 (9.8, 14.3)	8.2 (5.7, 10.7)	<0.001
<b>Sex</b>							0.2
F	738 (53%)	149 (51%)	239 (50%)	159 (52%)	78 (58%)	113 (58%)	
M	677 (47%)	142 (49%)	239 (50%)	148 (48%)	56 (42%)	82 (42%)	
<b>DHF/DSS</b>	66 (4.7%)	8 (2.7%)	30 (6.2%)	28 (9.0%)	0 (0%)	0 (0%)	<0.001
<b>DwWS/SD</b>	383 (27%)	62 (21%)	182 (38%)	103 (33%)	24 (18%)	12 (6.1%)	<0.001
<b>Time Since Last Infection</b>	4.54 (3.00, 6.00)	5.36 (3.00, 8.00)	3.72 (3.00, 4.00)	4.70 (3.00, 6.00)	5.35 (3.00, 6.00)	4.58 (2.00, 7.00)	<0.001
<b>Geometric Mean Titer (iELISA)</b>	384 (2, 126)	214 (2, 43)	514 (2, 197)	141 (2, 64)	675 (2, 289)	491 (2, 39)	<0.001
<b>Infection History</b>							
Naive	523 (38%)	139 (49%)	115 (24%)	134 (45%)	24 (19%)	111 (58%)	
DENV immune							
DENV	124 (9.0%)	29 (10%)	39 (8.2%)	21 (7.1%)	20 (16%)	15 (7.9%)	
ZIKV	306 (22%)	39 (14%)	180 (38%)	21 (7.1%)	41 (32%)	25 (13%)	
DENV-DENV	41 (3.0%)	13 (4.6%)	2 (0.4%)	18 (6.1%)	4 (3.1%)	4 (2.1%)	
DENV-ZIKV	71 (5.2%)	6 (2.1%)	43 (9.0%)	0 (0%)	17 (13%)	5 (2.6%)	
ZIKV-DENV	26 (1.9%)	7 (2.5%)	0 (0%)	4 (1.3%)	13 (10%)	2 (1.0%)	
2+DENV	60 (4.4%)	12 (4.3%)	10 (2.1%)	31 (10%)	1 (0.8%)	6 (3.1%)	
2+DENV-ZIKV	11 (0.8%)	1 (0.4%)	3 (0.6%)	1 (0.3%)	3 (2.3%)	3 (1.6%)	
DENV-ZIKV-2+DENV	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	
ZIKV-DENV-DENV	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	
2+DENV-ZIKV-DENV	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	

<sup>1</sup>Mean (IQR); n (%)

<sup>2</sup>Kruskal-Wallis rank sum test; Pearson's Chi-squared test

**Table S2. Estimated risk ratios of a dengue case by prior DENV and ZIKV infection histories, 2022-2023.**

Predictors	DENV Case			DENV1 Case			DENV3 Case			DENV4 Case			DwWS/SD		
	Risk Ratios	CI	p	Risk Ratios	CI	p	Risk Ratios	CI	p	Risk Ratios	CI	p	Incidence Rate Ratios	CI	p
(Intercept)	0.06	0.04 – 0.08	<b>&lt;0.001</b>	0.02	0.01 – 0.04	<b>&lt;0.001</b>	0.01	0.00 – 0.02	<b>&lt;0.001</b>	0.01	0.01 – 0.03	<b>&lt;0.001</b>	0.00	0.00 – 0.01	<b>&lt;0.001</b>
inf hist DD [DENV immune]	1.26	0.72 – 2.23	0.420	0.69	0.21 – 2.18	0.523	3.23	1.09 – 9.57	<b>0.034</b>	2.08	0.73 – 5.96	0.171	1.60	0.37 – 7.04	0.532
inf hist DD [DENV]	1.25	0.82 – 1.89	0.296	0.91	0.44 – 1.88	0.801	0.38	0.05 – 3.00	0.359	3.25	1.65 – 6.41	<b>0.001</b>	0.60	0.13 – 2.81	0.515
inf hist DD [ZIKV]	1.61	1.20 – 2.17	<b>0.002</b>	1.20	0.72 – 1.99	0.479	2.90	1.34 – 6.27	<b>0.007</b>	2.62	1.48 – 4.63	<b>0.001</b>	2.19	0.99 – 4.83	0.053
inf hist DD [DENV-DENV]	1.96	1.05 – 3.66	<b>0.036</b>	2.45	0.97 – 6.20	0.058	2.20	0.25 – 19.20	0.476	2.58	0.81 – 8.26	0.109	6.79	1.88 – 24.58	<b>0.003</b>
inf hist DD [DENV-ZIKV]	1.43	0.90 – 2.29	0.131	0.76	0.30 – 1.93	0.567	0.00	0.00 – Inf	0.984	3.96	1.93 – 8.12	<b>&lt;0.001</b>	3.46	1.24 – 9.65	<b>0.018</b>
inf hist DD [ZIKV-DENV]	0.79	0.47 – 1.34	0.384	0.48	0.19 – 1.24	0.130	1.76	0.43 – 7.13	0.431	1.60	0.68 – 3.76	0.282	0.82	0.18 – 3.69	0.797
inf hist DD [2+DENV]	0.37	0.09 – 1.50	0.164	0.39	0.05 – 2.94	0.364	0.00	0.00 – Inf	0.991	0.78	0.10 – 5.98	0.815	1.37	0.17 – 11.06	0.768
inf hist DD [2+DENV-ZIKV]	1.28	0.56 – 2.92	0.563	0.46	0.06 – 3.50	0.454	2.62	0.30 – 23.26	0.387	2.56	0.72 – 9.06	0.146	2.85	0.54 – 15.01	0.217
inf hist.DDDENV-ZIKV-2+DENV	0.00	0.00 – Inf	0.986	0.00	0.00 – Inf	0.992	0.00	0.00 – Inf	0.998	0.00	0.00 – Inf	0.992	0.00	0.00 – Inf	0.995
age	1.04	1.00 – 1.08	<b>0.029</b>	1.05	0.98 – 1.12	0.150	0.98	0.88 – 1.09	0.687	1.07	1.01 – 1.14	<b>0.023</b>	1.07	0.98 – 1.18	0.141
sex [M]	0.94	0.77 – 1.14	0.525	1.26	0.89 – 1.77	0.193	1.14	0.66 – 1.97	0.634	0.67	0.47 – 0.95	<b>0.025</b>	0.62	0.37 – 1.04	0.069
time per imm class	1.00	0.95 – 1.05	0.910	0.99	0.91 – 1.08	0.841	1.12	0.98 – 1.29	0.100	0.96	0.88 – 1.05	0.391	1.06	0.94 – 1.20	0.369
Observations	3411			3411			3411			3411			3411		
R <sup>2</sup> Nagelkerke	0.033			0.022			0.053			0.071			0.087		

**Table S3. Estimated risk ratios of a dengue case by prior DENV and ZIKV infection histories, 2004-2023**

Predictors	DENV1 Case			DENV2 Case			DENV3 Case			DENV4 Case			DwSSSD		
	Incidence Rate Ratios	CI	P	Risk Ratios	CI	P	Risk Ratios	CI	P	Incidence Rate Ratios	CI	P	Incidence Rate Ratios	CI	P
(Intercept)	0.00	0.00-0.01	<b>&lt;0.001</b>	0.00	0.00-0.00	<b>&lt;0.001</b>	0.00	0.00-0.00	<b>&lt;0.001</b>	0.00	0.00-0.00	<b>&lt;0.001</b>	0.00	0.00-0.00	<b>&lt;0.001</b>
inf hist DD [DENV immune]	1.04	0.87-1.25	0.649	0.57	0.38-0.86	<b>0.008</b>	1.84	1.33-2.55	<b>&lt;0.001</b>	0.99	0.71-1.40	0.973	2.65	1.03-6.83	<b>0.044</b>
inf hist DD [DENV]	1.17	0.94-1.45	0.160	0.80	0.51-1.27	0.346	2.09	1.44-3.05	<b>&lt;0.001</b>	0.78	0.48-1.29	0.341	3.28	1.64-6.57	<b>0.001</b>
inf hist DD [ZIKV]	1.87	1.54-2.27	<b>&lt;0.001</b>	1.04	0.66-1.63	0.856	3.62	2.60-5.04	<b>&lt;0.001</b>	2.60	1.39-4.85	<b>0.003</b>	2.66	1.49-4.76	<b>0.001</b>
inf hist DD [DENV;DENV]	1.45	1.03-2.04	<b>0.035</b>	1.37	0.72-2.61	0.335	0.37	0.09-1.51	0.164	2.40	1.37-4.23	<b>0.002</b>	2.64	0.80-8.68	0.110
inf hist DD [DENV;ZIKV]	1.47	1.09-1.99	<b>0.012</b>	0.57	0.24-1.37	0.210	2.53	1.64-3.91	<b>&lt;0.001</b>	0.00	0.00-Inf	0.997	4.05	1.93-8.49	<b>&lt;0.001</b>
inf hist DD [ZIKV;DENV]	0.85	0.55-1.34	0.490	0.42	0.18-1.02	0.055	0.00	0.00-Inf	0.990	1.47	0.47-4.66	0.510	1.67	0.70-4.00	0.249
inf hist DD (2+DENV)	0.64	0.48-0.86	<b>0.003</b>	0.41	0.22-0.79	<b>0.008</b>	0.55	0.28-1.09	0.086	0.96	0.60-1.56	0.883	0.76	0.10-5.86	0.790
inf hist DD (2+DENV;ZIKV)	0.82	0.44-1.54	0.533	0.32	0.04-2.36	0.263	0.45	0.14-1.46	0.183	2.33	0.30-18.05	0.418	2.60	0.71-9.56	0.151
inf hist DDDENV;ZIKV; 2+DENV	0.00	0.00-Inf	0.999	0.00	0.00-Inf	1.000	0.00	0.00-Inf	1.000	0.00	0.00-Inf	1.000	0.00	0.00-Inf	1.000
age	1.05	1.03-1.08	<b>&lt;0.001</b>	1.10	1.05-1.16	<b>&lt;0.001</b>	1.09	1.05-1.12	<b>&lt;0.001</b>	0.98	0.93-1.04	0.542	1.08	1.01-1.14	<b>0.020</b>
sex [M]	0.90	0.81-1.00	0.052	0.97	0.77-1.23	0.827	1.04	0.88-1.23	0.666	0.88	0.70-1.11	0.288	0.69	0.49-0.99	<b>0.042</b>
time per imm class	1.01	0.98-1.04	0.421	1.01	0.96-1.08	0.627	1.00	0.95-1.06	0.968	1.09	1.01-1.18	<b>0.020</b>	0.97	0.88-1.06	0.482
cohort year [2005]	3.53	2.01-6.22	<b>&lt;0.001</b>	2.58	1.16-5.73	<b>0.020</b>	8.03	2.44-26.41	<b>0.001</b>	0.94	0.00-Inf	1.000	0.00	0.00-Inf	1.000
cohort year [2006]	0.73	0.34-1.53	0.399	0.09	0.01-0.76	<b>0.027</b>	2.61	0.70-9.64	0.151	0.90	0.00-Inf	1.000	0.00	0.00-Inf	1.000
cohort year [2007]	3.58	2.03-6.32	<b>&lt;0.001</b>	0.09	0.01-0.74	<b>0.025</b>	19.11	5.96-61.28	<b>&lt;0.001</b>	0.86	0.00-Inf	1.000	0.00	0.00-Inf	1.000
cohort year [2008]	1.12	0.58-2.18	0.729	0.00	0.00-Inf	1.000	0.56	0.09-3.40	0.532	378254773.16	0.00-Inf	0.997	0.00	0.00-Inf	1.000
cohort year [2009]	7.80	4.54-13.39	<b>&lt;0.001</b>	1.18	0.49-2.83	0.711	2.54	0.68-9.52	0.166	2448918720.52	0.00-Inf	0.997	0.00	0.00-Inf	1.000
cohort year [2010]	4.67	2.67-8.16	<b>&lt;0.001</b>	0.00	0.00-Inf	1.000	4.61	1.32-16.06	<b>0.016</b>	1320414787.55	0.00-Inf	0.997	0.00	0.00-Inf	1.000
cohort year [2011]	1.46	0.76-2.79	0.255	0.31	0.09-1.06	0.063	0.00	0.00-Inf	0.985	361967558.36	0.00-Inf	0.997	0.00	0.00-Inf	1.000
cohort year [2012]	4.28	2.43-7.54	<b>&lt;0.001</b>	5.05	2.31-11.04	<b>&lt;0.001</b>	0.28	0.03-2.73	0.273	37368050.46	0.00-Inf	0.997	0.00	0.00-Inf	1.000
cohort year [2013]	1.75	0.94-3.27	0.080	1.28	0.53-3.08	0.582	1.79	0.43-7.34	0.421	77476627.39	0.00-Inf	0.997	1.04	0.06-18.11	0.979
cohort year [2014]	0.58	0.26-1.28	0.174	0.00	0.00-Inf	1.000	0.30	0.03-2.99	0.307	8811982.30	0.00-Inf	0.997	0.00	0.00-Inf	1.000
cohort year [2015]	1.51	0.80-2.86	0.202	0.00	0.00-Inf	1.000	7.23	2.11-24.78	<b>0.002</b>	0.69	0.00-Inf	1.000	0.00	0.00-Inf	1.000
cohort year [2016]	1.60	0.85-2.99	0.142	0.00	0.00-Inf	0.999	2.48	0.65-9.45	0.184	0.69	0.00-Inf	1.000	0.00	0.00-Inf	1.000
cohort year [2017]	0.15	0.05-0.44	<b>0.001</b>	0.00	0.00-Inf	0.999	0.00	0.00-Inf	0.983	0.61	0.00-Inf	1.000	0.00	0.00-Inf	0.999
cohort year [2018]	0.36	0.16-0.81	<b>0.014</b>	0.00	0.00-Inf	0.999	0.44	0.09-2.26	0.325	0.57	0.00-Inf	1.000	0.00	0.00-Inf	0.999
cohort year [2019]	11.52	6.67-19.89	<b>&lt;0.001</b>	0.00	0.00-Inf	1.000	48.67	14.75-160.55	<b>&lt;0.001</b>	0.55	0.00-Inf	1.000	0.00	0.00-Inf	1.000
cohort year [2020]	0.19	0.07-0.53	<b>0.002</b>	0.00	0.00-Inf	0.999	0.38	0.06-2.35	0.297	0.58	0.00-Inf	1.000	0.00	0.00-Inf	0.999
cohort year [2021]	0.12	0.03-0.41	<b>0.001</b>	0.10	0.02-0.50	<b>0.005</b>	0.00	0.00-Inf	0.983	0.56	0.00-Inf	1.000	0.00	0.00-Inf	1.000
cohort year [2022]	13.06	7.49-22.77	<b>&lt;0.001</b>	6.76	3.00-15.27	<b>&lt;0.001</b>	1.60	0.40-6.42	0.508	70588112.68	0.00-Inf	0.997	97.75	11.66-819.56	<b>&lt;0.001</b>
<b>Random Effects</b>															
$\sigma^2$	5.05		NA			NA			6.76		7.50		0.00		
tau	0.00	<small>case ids</small>		0.00	<small>case ids</small>		1.00	<small>case ids</small>		0.00	<small>case ids</small>		0.00	<small>case ids</small>	
ICC	0.00												0.00		
N	9165	<small>case ids</small>		9165	<small>case ids</small>		9165	<small>case ids</small>		9165	<small>case ids</small>		9165	<small>case ids</small>	
Observations	66842		67438		67438		67438		67438		67438		67438		67438
Marginal R <sup>2</sup> / Conditional R <sup>2</sup>	0.303 / 0.303		NA		NA		NA		0.943 / NA		0.909 / 0.909		1.000 / 1.000		1.000 / 1.000





**Table S5. Estimated risk of symptomatic DENV infection by pre-existing DENV iELISA titers, 2022-2023.**

Predictors	DENV Case			DENV1 Case			DENV3 Case			DENV4 Case			DwWS/SD		
	Risk Ratios	CI	P	Risk Ratios	CI	P	Risk Ratios	CI	P	Risk Ratios	CI	P	Risk Ratios	CI	P
(Intercept)	0.06	0.04 – 0.08	<0.001	0.02	0.01 – 0.04	<0.001	0.01	0.00 – 0.02	<0.001	0.01	0.01 – 0.02	<0.001	0.00	0.00 – 0.01	<0.001
gm titers cat [<21]	1.62	1.21 – 2.17	<b>0.001</b>	1.10	0.65 – 1.82	0.714	2.91	1.39 – 6.09	<b>0.005</b>	2.76	1.55 – 4.96	<b>0.001</b>	2.16	1.01 – 4.61	<b>0.047</b>
gm.titers.cat21-80	1.64	1.12 – 2.34	<b>0.009</b>	1.27	0.66 – 2.32	0.459	1.90	0.69 – 5.26	0.215	3.59	1.84 – 6.89	<0.001	1.67	0.59 – 4.23	0.305
gm.titers.cat81-320	1.39	0.92 – 2.06	0.106	0.79	0.35 – 1.61	0.542	0.68	0.15 – 3.21	0.629	4.22	2.18 – 8.11	<0.001	1.80	0.62 – 4.71	0.254
gm.titers.cat321-1280	1.10	0.69 – 1.70	0.670	0.72	0.31 – 1.54	0.430	1.08	0.28 – 4.18	0.906	3.07	1.46 – 6.28	<b>0.003</b>	2.26	0.82 – 5.79	0.102
gm titers cat [>1280]	0.68	0.41 – 1.11	0.134	0.38	0.14 – 0.91	<b>0.041</b>	0.00	0.00 – Inf	0.984	2.08	0.94 – 4.49	0.067	0.69	0.17 – 2.32	0.572
age	1.04	1.00 – 1.07	<b>0.040</b>	1.05	0.99 – 1.12	0.113	1.00	0.90 – 1.10	0.961	1.05	0.99 – 1.11	0.084	1.10	1.01 – 1.19	<b>0.032</b>
sex [M]	0.91	0.74 – 1.10	0.326	1.21	0.86 – 1.71	0.272	1.10	0.64 – 1.91	0.719	0.66	0.46 – 0.93	<b>0.020</b>	0.62	0.37 – 1.01	0.060
time per imm class	1.01	0.97 – 1.06	0.614	0.99	0.92 – 1.07	0.832	1.09	0.97 – 1.23	0.165	1.01	0.93 – 1.08	0.891	1.05	0.94 – 1.16	0.378
Observations	3499			3499			3499			3499			3499		
R <sup>2</sup> Nagelkerke	0.027			0.015			0.056			0.059			0.048		

**Table S6. Estimated risk of symptomatic DENV infection by pre-existing DENV iELISA titers, 2004-2023.**

Predictors	DENV Case			DENV1 Case			DENV2 Case			DENV3 Case			DENV4 Case			DwWS/SD		
	Risk Ratios	CI	p	Risk Ratios	CI	p	Incidence Rate Ratios	CI	p	Risk Ratios	CI	p	Incidence Rate Ratios	CI	p	Risk Ratios	CI	p
(Intercept)	0.00	0.00 – 0.01	<0.001	0.00	0.00 – 0.00	<0.001	0.00	0.00 – 0.00	<0.001	0.00	0.00 – 0.00	0.994	0.00 – 0.00	<0.001	0.00	0.00 – 0.00	<0.001	
gm titers cat [ $<21$ ]	1.37	1.15 – 1.63	<0.001	0.89	0.61 – 1.31	0.560	1.71	1.19 – 2.45	<b>0.003</b>	1.67	1.16 – 2.42	<b>0.006</b>	2.90	1.61 – 5.22	<0.001	1.83	1.27 – 2.64	<b>0.001</b>
gm.titers.cat21-80	1.62	1.37 – 1.92	<0.001	0.95	0.64 – 1.40	0.796	3.32	2.47 – 4.48	<0.001	1.22	0.84 – 1.77	0.286	3.59	1.83 – 7.03	<0.001	2.97	2.15 – 4.10	<0.001
gm.titers.cat81-320	1.33	1.12 – 1.58	<b>0.001</b>	0.62	0.41 – 0.95	<b>0.028</b>	2.71	2.01 – 3.67	<0.001	0.94	0.64 – 1.38	0.767	4.45	2.29 – 8.65	<0.001	2.34	1.67 – 3.27	<0.001
gm.titers.cat321-1280	0.96	0.77 – 1.20	0.721	0.35	0.19 – 0.63	<0.001	2.24	1.57 – 3.19	<0.001	0.51	0.29 – 0.90	<b>0.019</b>	3.14	1.50 – 6.58	<b>0.002</b>	1.68	1.12 – 2.53	<b>0.013</b>
gm titers cat [ $>1280$ ]	0.64	0.48 – 0.84	<b>0.002</b>	0.25	0.12 – 0.52	<0.001	0.99	0.59 – 1.66	0.958	0.44	0.20 – 0.94	<b>0.034</b>	2.13	0.96 – 4.71	0.062	1.02	0.59 – 1.76	0.932
age	1.06	1.04 – 1.08	<0.001	1.11	1.06 – 1.17	<0.001	1.08	1.04 – 1.11	<0.001	1.01	0.96 – 1.06	0.672	1.05	0.99 – 1.11	0.078	1.08	1.05 – 1.12	<0.001
sex [M]	0.88	0.79 – 0.98	<b>0.015</b>	0.94	0.75 – 1.19	0.620	1.01	0.84 – 1.21	0.951	0.88	0.70 – 1.10	0.262	0.68	0.48 – 0.97	<b>0.034</b>	0.81	0.66 – 0.99	<b>0.039</b>
time per imm class	1.00	0.98 – 1.03	0.759	1.00	0.94 – 1.05	0.892	0.98	0.94 – 1.03	0.483	1.06	1.00 – 1.13	0.071	1.01	0.94 – 1.09	0.757	1.01	0.96 – 1.06	0.773
cohort year [2005]	3.50	1.99 – 6.14	<0.001	2.61	1.18 – 5.77	<b>0.018</b>	7.80	2.37 – 25.74	<b>0.001</b>	0.00	0.00 – Inf	1.000	0.00	0.00 – Inf	0.999	1.69	0.15 – 18.65	0.668
cohort year [2006]	0.70	0.34 – 1.48	0.354	0.10	0.01 – 0.76	<b>0.027</b>	2.47	0.67 – 9.13	0.176	0.00	0.00 – Inf	1.000	0.00	0.00 – Inf	1.000	0.78	0.05 – 12.48	0.861
cohort year [2007]	3.40	1.94 – 5.96	<0.001	0.09	0.01 – 0.72	<b>0.023</b>	17.01	5.31 – 54.45	<0.001	0.00	0.00 – Inf	1.000	0.00	0.00 – Inf	1.000	11.85	1.56 – 89.82	<b>0.017</b>
cohort year [2008]	1.05	0.55 – 2.03	0.876	0.00	0.00 – Inf	0.995	0.51	0.09 – 3.09	0.467	136901815.68	0.00 – Inf	0.996	0.00	0.00 – Inf	0.999	3.49	0.41 – 29.96	0.255
cohort year [2009]	7.28	4.28 – 12.38	<0.001	1.16	0.49 – 2.74	0.731	2.19	0.59 – 8.16	0.242	915708882.92	0.00 – Inf	0.995	0.00	0.00 – Inf	1.000	43.85	6.06 – 317.38	<0.001
cohort year [2010]	4.36	2.52 – 7.55	<0.001	0.00	0.00 – Inf	0.995	4.00	1.16 – 13.81	<b>0.028</b>	486842043.10	0.00 – Inf	0.995	0.00	0.00 – Inf	0.999	17.43	2.36 – 128.92	<b>0.005</b>
cohort year [2011]	1.36	0.72 – 2.57	0.346	0.31	0.09 – 1.03	0.055	0.00	0.00 – Inf	0.999	128772175.51	0.00 – Inf	0.996	0.00	0.00 – Inf	1.000	3.70	0.43 – 31.86	0.234
cohort year [2012]	4.04	2.33 – 7.02	<0.001	5.02	2.37 – 10.65	<0.001	0.25	0.03 – 2.47	0.238	13462059.59	0.00 – Inf	0.996	0.00	0.00 – Inf	0.999	13.74	1.83 – 103.04	<b>0.011</b>
cohort year [2013]	1.71	0.93 – 3.16	0.085	1.34	0.57 – 3.13	0.498	1.69	0.42 – 6.85	0.461	28828392.88	0.00 – Inf	0.996	0.87	0.05 – 14.15	0.923	8.69	1.12 – 67.38	<b>0.039</b>
cohort year [2014]	0.58	0.26 – 1.27	0.172	0.00	0.00 – Inf	0.996	0.30	0.03 – 2.91	0.299	22172025.15	0.00 – Inf	0.996	0.00	0.00 – Inf	1.000	0.00	0.00 – Inf	0.999
cohort year [2015]	1.56	0.84 – 2.91	0.160	0.00	0.00 – Inf	0.995	7.59	2.26 – 25.53	<b>0.001</b>	0.00	0.00 – Inf	1.000	0.00	0.00 – Inf	1.000	3.84	0.44 – 33.17	0.221
cohort year [2016]	1.70	0.92 – 3.14	0.088	0.00	0.00 – Inf	0.995	2.83	0.76 – 10.61	0.122	0.00	0.00 – Inf	1.000	0.00	0.00 – Inf	0.999	0.00	0.00 – Inf	0.999
cohort year [2017]	0.19	0.06 – 0.56	<b>0.003</b>	0.00	0.00 – Inf	0.995	0.00	0.00 – Inf	0.999	0.00	0.00 – Inf	1.000	0.00	0.00 – Inf	0.999	0.00	0.00 – Inf	0.999
cohort year [2018]	0.46	0.20 – 1.02	0.055	0.00	0.00 – Inf	0.995	0.75	0.15 – 3.76	0.732	0.00	0.00 – Inf	1.000	0.00	0.00 – Inf	0.999	0.00	0.00 – Inf	0.999
cohort year [2019]	14.44	8.58 – 24.31	<0.001	0.00	0.00 – Inf	0.995	64.24	20.40 – 202.35	<0.001	0.02	0.00 – Inf	1.000	0.00	0.00 – Inf	0.999	91.08	12.67 – 654.66	<0.001
cohort year [2020]	0.23	0.08 – 0.64	<b>0.005</b>	0.00	0.00 – Inf	0.995	0.47	0.08 – 2.85	0.414	0.00	0.00 – Inf	1.000	0.00	0.00 – Inf	1.000	0.00	0.00 – Inf	1.000
cohort year [2021]	0.14	0.04 – 0.49	<b>0.002</b>	0.11	0.02 – 0.55	<b>0.007</b>	0.00	0.00 – Inf	0.999	0.02	0.00 – Inf	1.000	0.00	0.00 – Inf	1.000	0.00	0.00 – Inf	0.999
cohort year [2022]	15.37	9.07 – 26.04	<0.001	7.42	3.48 – 15.81	<0.001	1.97	0.51 – 7.57	0.322	317888094.00	0.00 – Inf	0.995	93.98	12.72 – 694.26	<0.001	37.86	5.18 – 276.75	<0.001
<b>Random Effects</b>																		
$\sigma^2$	NA			NA			6.32			NA			7.59			NA		
$\tau_{00}$	0.00	case.ids		0.00	case.ids		0.00	case.ids		0.00	case.ids		0.00	case.ids		0.00	case.ids	
ICC							0.00											
N	9164	case.ids		9164	case.ids		9164	case.ids		9164	case.ids		9164	case.ids		9164	case.ids	
Observations	67030			67638			67638			67638			67638			67638		
Marginal $R^2$ / Conditional $R^2$	NA			NA			0.915 / 0.915			NA			0.899 / 0.899			NA		

**Table S7. Half-lives of antibody titers for a given infection history, 2004-2023.**

Infection History	Average titer magnitude at 1 year post last infection*	Slope(s)**	95% Confidence Intervals	Half-lives ***	Inflection Point(s)****
DENV Immune	2.48[2.44,2.52]	<b>-0.12</b> 0.04	<b>(-0.12, -0.11)</b> (-0.002, 0.07)	5.78 -17.33	8.79
DENV	1.87[1.83,1.92]	0.02 <b>-0.05</b>	(-0.04, 0.08) <b>(-0.06, -0.03)</b>	-34.66 13.86	2.3
ZIKV	0.85[0.81,0.89]	<b>0.30</b> <b>-0.19</b>	<b>(0.28, 0.33)</b> <b>(-0.23, -0.16)</b>	-2.31 3.65	3.2
DENV-DENV	2.71[2.61,2.80]	<b>-0.40</b> <b>-0.04</b>	<b>(-0.55, -0.26)</b> <b>(-0.16, -0.02)</b>	1.73 17.33	2.31
DENV-ZIKV	3.01[2.98,3.13]	<b>-0.08</b> -0.18	<b>(-0.11, -0.05)</b> (-0.89, 0.53)	8.66 3.85	5
ZIKV-DENV	3.34[3.25,3.44]	<b>-0.28</b>	<b>(-0.35, -0.21)</b>	2.48	None
2+DENV	2.96[2.90,3.01]	<b>-0.36</b> <b>-0.03</b>	<b>(-0.44, -0.29)</b> <b>(-0.05, -0.02)</b>	1.93 23.10	2.3
2+DENV-ZIKV	3.56[3.44,3.67]	<b>-0.41</b> 0.16 -0.23	<b>(-0.58, -0.23)</b> (-0.05, 0.37) (-0.49, 0.03)	1.69 -4.33 3.01	2.4 4.4

\*Predicted log<sub>10</sub>(DENV iELISA titer) and confidence intervals at 1 year after last infection.

\*\* log<sub>10</sub>(DENV iELISA titer)/year. Significant slopes are bolded.

\*\*\*Half-lives were calculated by computing log(2) divided by slope (log(2)/slope). Negative half-lives indicate an increase in titer magnitude.

\*\*\*\* Inflection points were calculated in years